I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA
Rivista di Dermatologia e Malattie Sessualmente Trasmesse
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Giornale Italiano di Dermatologia e Venereologia 2016 Nov 15
Are anti-epidermal transglutaminase (eTG) antibodies titre correlated with dermatitis herpetiformis lesions during the disease follow-up?
Emanuele COZZANI 1, Fabrizio PAPPALARDO 1, Giulia GASPARINI 1, Fabio GALLO 2, Francesco DRAGO 1, Aurora PARODI 1 ✉
1 Section of Dermatology, Di.S.Sal, AOU San Martino-IRCCS-IST, Genoa, Italy; 2 Biostatistics Unit, Di.S.Sal, AOU San Martino-IRCCS-IST, Genoa, Italy
BACKGROUND: Dermatitis herpetiformis (DH) is characterized by the presence of anti-tissue transglutaminase (tTG) IgA antibodies in patient sera. In 2002, anti-epidermal transglutaminase (eTG) antibodies have been identified in DH patients. Nowadays, their role is still controversial.
AIM: To evaluate any association between presence/absence of anti-eTG antibodies and cutaneous manifestations during the follow-up.
METHODS: Anti-eTG and anti-tTG antibodies from 13 patients on gluten-free diet (GFD) were studied during follow-up on ELISA. Cutaneous manifestations baseline differences among age, gender, anti-eTG IgA, anti-tTG IgA, and treatment groups were tested by the Wilcoxon Rank Sum and Fisher's exact test. In order to investigate the associations of cutaneous manifestations with age, gender, anti-eTG IgA, anti-tTG IgA, and treatment groups the Mixed-Effects (ME) model was performed. To test whether the cutaneous manifestations in treatment groups were different according to the anti-eTG levels, an Exploratory Interaction Analysis was carried out using the ME Model.
RESULTS: Seven patients (53.85%) had an anti-eTG value greater than 22 AU/ml, while six (46.15%) were classified as anti-eTG value <22 AU/ml. A significant correlation between anti-eTG antibodies and cutaneous manifestations was observed. No significant cutaneous manifestations differences existed in treatment groups according to the anti-eTG antibodies levels. Anti-tTG antibodies resulted negative in every patient serum.
CONCLUSIONS: Anti-eTG antibodies persist much longer after the elimination of gluten from the patients diet compared to anti-tTG antibodies and seem to be a valid marker for monitoring the disease during the follow-up.